Silexion Therapeutics Corp effected a 1-for-24 reverse share split of its ordinary shares effective after the close of trading on November 10, 2026. In connection with the split, the company adjusted its outstanding warrants, increasing the exercise price 24-fold to $372,600.00 per post-split share and reducing the number of shares issuable per warrant to 1/24th of a share.
Silexion Therapeutics announced a 1-for-24 reverse share split of its ordinary shares, effective after the market close on November 10, 2026. The split is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. Trading on a split-adjusted basis will begin on November 11, 2026, under the existing ticker symbol SLXN.
Silexion Therapeutics Corp shareholders approved a 1-for-24 reverse stock split of the company's ordinary shares, increasing the par value from $0.135 to $3.24 per share. Additionally, shareholders approved an increase in authorized share capital from 15.9 million to 515.9 million ordinary shares. The reverse split and capital increase were finalized at a reconvened extraordinary general meeting on October 26, 2026.